H.C. Wainwright Elevates Adlai Nortye to Buy, Pins $16 Price Target
H.C. Wainwright upgraded Adlai Nortye Ltd. (ANL) from Neutral to Buy and assigned a $16.00 price target, citing the company’s clinical portfolio and recent business development activity. The firm’s valuation model places the greatest weight on AN9025, and highlights upcoming clinical readouts and pipeline progress as potential catalysts. Market met…